U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H19NO
Molecular Weight 241.3282
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LITOXETINE

SMILES

C(OC1CCNCC1)C2=CC3=C(C=CC=C3)C=C2

InChI

InChIKey=MJJDYOLPMGIWND-UHFFFAOYSA-N
InChI=1S/C16H19NO/c1-2-4-15-11-13(5-6-14(15)3-1)12-18-16-7-9-17-10-8-16/h1-6,11,16-17H,7-10,12H2

HIDE SMILES / InChI

Molecular Formula C16H19NO
Molecular Weight 241.3282
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Litoxetine is a selective serotonin (5-HT) reuptake inhibitor (SSRI) and mixed serotonin agonist-antagonist, which makes it particularly appropriate for treating continence dysfunctions. Litoxetine at concentrations without antimuscarinic properties (10 nM-1 microM) caused concentration-dependent relaxations in the rat isolated oesophageal muscularis mucosae, which reduced carbachol tone up to 37%. Higher litoxetine concentrations (3 microM-300 microM) were associated with marked relaxation up to the abolition of carbachol tone. The antimuscarinic activity of litoxetine, previously demonstrated in the isolated guinea-pig intestine, played a role in the rat isolated oesophageal muscularis mucosae at concentrations greater than 1 microM. The 5-HT-releasing action of litoxetine could account for the potentation by litoxetine of 5-HT-induced relaxation in tissues from untreated rats, which was reversed by pCPA treatment. Litoxetine is in phase II clinical trial for the treatment of urinary incontinence.

Originator

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
2.5 mg, 5 mg, 10 mg, 25 mg or placebo twice daily on days 1-4 and once on day 5
Route of Administration: Oral
Substance Class Chemical
Record UNII
9980ST005G
Record Status Validated (UNII)
Record Version